Genprex, Inc. Files 8-K with Corporate Updates
Ticker: GNPX · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1595248
Sentiment: neutral
Topics: corporate-filing, 8-K
Related Tickers: GNPX
TL;DR
Genprex filed an 8-K on 10/15/24 detailing corporate info. Nothing major, just housekeeping.
AI Summary
Genprex, Inc. filed an 8-K on October 15, 2024, reporting on other events and financial statements. The filing details the company's corporate structure, including its incorporation in Delaware and its principal executive offices located at 3300 Bee Cave Road, #650-227, Austin, TX 78746. The company's IRS Employer Identification Number is 90-0772347.
Why It Matters
This filing provides essential corporate information and updates for Genprex, Inc., which is crucial for investors and stakeholders to understand the company's structure and reporting status.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain significant new business developments or financial risks.
Key Players & Entities
- Genprex, Inc. (company) — Registrant
- October 15, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 3300 Bee Cave Road , #650-227 , Austin , TX 78746 (address) — Address of principal executive offices
- 90-0772347 (identifier) — I.R.S. Employer Identification Number
- 512-537-7997 (phone_number) — Registrant's telephone number
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is October 15, 2024.
In which state is Genprex, Inc. incorporated?
Genprex, Inc. is incorporated in Delaware.
What is the company's principal executive office address?
The principal executive offices are located at 3300 Bee Cave Road, #650-227, Austin, TX 78746.
What is the IRS Employer Identification Number for Genprex, Inc.?
The IRS Employer Identification Number is 90-0772347.
What is the telephone number for Genprex, Inc.?
The registrant's telephone number, including area code, is (512) 537-7997.
Filing Stats: 1,266 words · 5 min read · ~4 pages · Grade level 13.2 · Accepted 2024-10-15 09:29:57
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
Filing Documents
- gnpx20241009_8k.htm (8-K) — 34KB
- 0001437749-24-031202.txt ( ) — 165KB
- gnpx-20241015.xsd (EX-101.SCH) — 3KB
- gnpx-20241015_def.xml (EX-101.DEF) — 11KB
- gnpx-20241015_lab.xml (EX-101.LAB) — 15KB
- gnpx-20241015_pre.xml (EX-101.PRE) — 11KB
- gnpx20241009_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On October 15, 2024, Genprex, Inc. ("Genprex" or the "Company") issued a press release in which it announced that Genprex has completed the 0.09 mg/kg dose group of the Phase 1 dose escalation portion of the Acclaim-3 clinical trial of Reqorsa Gene Therapy (quaratusugene ozeplasmid) in combination with Genentech's Tecentriq (atezolizumab) as maintenance therapy for patients with extensive stage small cell lung cancer ("ES-SCLC") who developed tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. In addition, the Safety Review Committee ("SRC") has approved escalation to the highest dose group of 0.12 mg/kg. The SRC is comprised of three physicians who are principal investigators in the trial. The SRC may recommend that the trial continue at the same dose or at a lower dose, that it escalate to a higher dose, or that the study be terminated altogether due to safety concerns. In the Phase 1 dose escalation portion of the Acclaim-3 clinical trial, patients are treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. The primary endpoint of the Phase 1 escalation portion is to determine the maximum tolerated dose or recommended Phase 2 dose. There were no dose limiting toxicities in this dose group and the SRC recommended moving up to the highest dose group planned in the trial. The Phase 1 portion of the trial has two dose groups: 0.09 mg/kg, which has been completed, and 0.12 mg/kg which will now be enrolled. After the Phase 1 portion is complete, the Phase 2 expansion portion will enroll 50 patients at 10 to 15 U.S sites. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. The primary endpoint of the Phase 2 portion is to determine the 18-week progression-free survival rate from the time of the start of maintenance therapy with REQORSA and Tecentriq in patients with ES-SCLC. Patients will also
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: October 15, 2024 By: /s/ Ryan Confer Ryan Confer Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)